Mrsa | New Drug Hope Over MRSA And C Diff.

(UKPA)- 9 hours ago

Scientists are developing an “extremely promising” treatment for MRSA and Clostridium difficile.

The new antibiotic is being developed by MGB Biopharma, a biopharmaceutical company which has licensed technology from the University of Strathclyde.

The company is working on a new compound called MGB BP-3 which it says has proved to be more effective in killing and preventing C Diff. than vancomycin, currently one of the most widely used treatments against the bacterium.

Clinical trials are now scheduled for 2012.

Dr Miroslav Ravic, chief executive officer of Glasgow-based MGB Biopharma, said: “It seems we are hearing too much about Clostridium difficile infections these days in the press, especially those acquired in hospital by elderly patients in whom the infection can be fatal.

“This is clearly an area of high unmet need as a result of the rise of resistant bacteria which are threatening to outpace the availability of new drugs able to successfully treat these life-threatening infections. We are very excited that MGB BP-3 shows such a promising response against this troublesome and difficult-to-treat infection.

“We are committed to developing a specific oral drug for the treatment of Clostridium

Click here to view rest of article from original site

Staphaseptic First Aid Bactericide Gel 2 Oz (56.7 G)  by Staphaseptic Staphaseptic First Aid Bactericide Gel 2 Oz (56.7 G)  by Staphaseptic

27 new from $6.98
Mrsa  by John A. Weigelt Mrsa  by John A. Weigelt

13 new from $59.94

Facebook Twitter Email